Synektik

Synektik EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Synektik (SNT.WA) as of Oct 31, 2026 is 157.02 M PLN. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 106.94 M PLN — a change of 46.83% (higher).

EBITDA

157.02 MPLN

YoY

46.83%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Synektik is 2025 157.02 M PLN. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Synektik was 2024 106.94 M PLN. It decreases by 46.83% higher compared to the previous year.

The Synektik EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
11.63 M PLN
Jan 1, 2019
12.72 M PLN
Jan 1, 2020
12.03 M PLN
Jan 1, 2021
11.19 M PLN
Jan 1, 2022
7.04 M PLN
Jan 1, 2023
67.86 M PLN
Jan 1, 2024
106.94 M PLN
Jan 1, 2025
157.02 M PLN
The Synektik EBITDA history
YEAREBITDAYoY
157.02 MPLN+46.83%
106.94 MPLN+57.59%
67.86 MPLN+864.11%
7.04 MPLN-37.08%
11.19 MPLN-7.02%
12.03 MPLN-5.38%
12.72 MPLN+9.32%
11.63 MPLN+225.39%
3.57 MPLN+67.97%
2.13 MPLN-473.86%
-569,223.76PLN-110.54%
5.40 MPLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Synektik Stock analysis

What does Synektik do? Synektik SA generates revenue through its PACS software, which enables diagnostic imaging laboratories to operate efficiently. The company also sells medical equipment and provides services through its imaging equipment services center. Synektik SA partners with Siemens and holds a 100% stake in Miedzynarodowe Centra Medyczne Inwestycje Sp z o o, which it acquired by raising its stake on November 28, 2013. The firm's research laboratory conducts acceptance and specialist tests on X-ray equipment, contributing to its service offerings. The primary buyers of Synektik SA's products include diagnostic imaging laboratories that require PACS software for their operations. Medical equipment is sold to healthcare facilities, while the research laboratory services are utilized by entities needing X-ray equipment testing. The company's partnership with Siemens supports its medical equipment sales and services. Synektik SA's revenue streams are derived from software licensing, medical equipment sales, and specialized testing services. The company's focus on diagnostic imaging solutions and its ownership of Miedzynarodowe Centra Medyczne Inwestycje Sp z o o position it within the medical technology sector, targeting healthcare providers and imaging laboratories. Synektik is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Synektik stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Synektik is 157.02 M PLN in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Synektik changed from 106.94 M PLN to 157.02 M PLN, representing a 46.83% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Synektik since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Synektik historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Synektik

All Key Metrics — Synektik